| Id: | acc3407 |
| Group: | 2sens |
| Protein: | IkappaBalpha |
| Gene Symbol: | NFKBIA |
| Protein Id: | P25963 |
| Protein Name: | IKBA_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser32 |
| Site Sequence: | ERLLDDRHDSGLDSMKDEEYE |
| Disease Category: | Immune system diseases |
| Disease: | Rheumatoid Arthritis |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | licochalcone A (LCA) |
| Drug Info: | Licochalcone A (LCA) is a drug that may have certain pharmacological activities. It could potentially be used in medical research and treatment. |
| Effect: | modulate |
| Effect Info: | "Licochalcone A blocks the NF-κB pathway by inhibiting the phosphorylation and degradation of IκBα, thereby slowing down the pathological progression of RA." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 29864947 |
| Sentence Index: | 29864947_5-6 |
| Sentence: | "Interestingly, IKKbeta phosphorylation was not detectable in RASFs, indicating that LCA altered the morphology, ultrastructure and stiffness of the RASF membrane by inhibiting NF-kappaB activation independent of IKKbeta phosphorylation. Antigen-induced arthritis (AIA) was established in Sprague Dawley (SD) rats to validate the anti-arthritic effect of LCA, and LCA significantly decreased both the arthritis scores and paw swelling in the AIA rats, suggesting that LCA inhibits the progression and development of arthritis in vivo." |
Sequence & Structure:
MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| NFKBIA-Ser32 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 32 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
| T | 32 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
